期刊
KIDNEY MEDICINE
卷 1, 期 3, 页码 139-143出版社
ELSEVIER
DOI: 10.1016/j.xkme.2019.03.005
关键词
-
资金
- NHLBI NIH HHS [R01 HL132325] Funding Source: Medline
Eculizumab is an emerging therapy for atypical hemolytic uremic syndrome (aHUS). Early identification and treatment of recurrent aHUS after kidney transplantation requires a high clinical suspicion but results in improved graft function and patient outcome. We present a patient who developed recurrent aHUS after kidney transplantation that responded to eculizumab therapy. A kidney biopsy was performed to confirm resolution of thrombotic microangiopathy 8 weeks after eculizumab treatment initiation and revealed no features of thrombotic microangiopathy. Instead, the biopsy revealed monoclonal immuno-globulin G (IgG)4/2 kappa deposition in the glomerular tufts, vasculature, and atrophic tubular basement membranes. IgG4/2 kappa deposits are a rare pathologic finding following eculizumab therapy, and the long-term effect of these deposits on kidney function remains unknown. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据